Tacrolimus dosage requirements in living donor liver transplant recipients with small-for-size grafts

Table 1 Patient demographics

	Group S	Group N	P
Recipients’ age (yr)	41.9 ± 11.6	43.4 ± 7.3	NS (0.695)
Donors’ age (yr)	28.6 ± 4.4	31.8 ± 9.5	NS (0.246)
Sex (Male/female)	6/2	39/7	NS (0.864)
MELD score			NS (0.911)
1-13	5	25
14-24	2	14
≥ 25	1	7
Indications for LDLT			NS (1.000)
Cirrhosis	3	15
HCC	4	24
FHF	1	5
Others	0	2
Rejection	1/8	4/46	NS (0.567)
Body weight	66.6 ± 7.6	61.7 ± 9.8	NS (0.244)
Biliary anastomosis			NS (0.484)
Roux-en-Y	1 (12.5)	3 (7)
Choledochocholedochostomy	7 (87.5)	43 (93)

NS: Not significant.

Table 2 Medication interactions

Medication interaction factors	Group S	Group N	P
Patients administered interacting drugs	2/8	7/46	NS
Total number of treatment courses	4	9	NS
Interacting drugs
Fluconazole	1	3	NS
Felodipine	1	2	NS
Lansoprazole	2	4	NS
Average length of therapy (d)	7	9.5	NS
No. of treatment courses on postoperative day			NS
1-30	3	5
31-60	1	3
61-180	0	1

Table 3 Liver function and kidney function test values

	Month
	1	2	3	4	5	6
Group N
ALT (IU/L)	115.9	67.9	43.6	39	38	37.7
AST (IU/L)	52.7	47	34.9	39.3	36.1	38.9
TB (μmol/L)	23.1	18.5	17.2	14.9	17.6	17.9
Alb (g/L)	35.1	40.7	42.9	41.2	43	42.7
Cr (μmol/L)	55.5	55.1	59	55.7	54.1	52.3
Group S
ALT (IU/L)	124.2	78.2	46.8	41.5	34.4	39.7
AST (IU/L)	62.6	53.4	42.5	39.9	38.8	39.3
TB (μmol/L)	33.2	22.5	19.6	18.1	16	15.6
Alb (g/L)	33.6	39.7	42.3	42.7	43.9	42.9
Cr (μmol/L)	56.9	58.3	61	61.7	64.5	63